A Canadian biopharmaceutical company that is developing a potential first-to-market drug to treat kidney inflammation caused by lupus has selected an office building in the biotech hub of north Rockville, Maryland, to house its new U.S. commercial center of operations.
RELATED ARTICLES
This news story is available exclusively to CoStar subscribers.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In
IN THIS ARTICLE
- Properties